ClinicalTrials.gg
RecruitingNCT07854327LymphDADUpdated Oct 2, 2026

Restoring Cervical Lymphatic Drainage in Alzheimer's Disease

An interventional study of Cervical lymphovenous anastomosis (LVA) and Cervical lymphovenous anastomosis (LVA) in Alzheimer and Alzheimer Dementia (AD), sponsored by University of Siena. Recruiting at 1 site in Italy. Per ClinicalTrials.gov, last updated 2026-10-02.

Sponsored by University of Siena · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jul 2026; still recruiting 4 months later.
Updated Oct 2, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
5
Allocation
Not applicable
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 206 studies in Alzheimer Disease with a site in Italy — 53 open to participants now, 72 under way, 19 of them phase 3. Alzheimer Disease · Italy.

Planned enrollment
169th of 170
5 · median 328
Started
2026
with 10 others
No phase
54 of 206
20 open now
Primary completion
2028-07
later than 52 of 71 live
Registered
203rd of 206
by date

Among the 206 studies in Alzheimer Disease with a site in Italy, this one is the 169th largest by planned enrollment of the 170 interventional ones that give a count, is one of 11 that started in 2026, is one of 54 with no phase, reaches primary completion later than 52 of the 71 other live ones, and was the 203rd registered.

Alzheimer Disease

3,972 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

53 of the 206 studies in Alzheimer Disease with a site in Italy are open now. Recruiting first, the newest first:

47 more — sign in →

All 53 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 645 Alzheimer Disease studies recruiting now, 282 (44%) set no upper age limit and 57 (9%) stop at 75 or younger; 34 take children under 18; 288 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 206 studies in Alzheimer Disease with a site in Italy, or all of them as a file.
02

Study summary

Alzheimer's disease (AD) is a progressive neurodegenerative disorder associated with the accumulation of abnormal proteins, including amyloid-beta and tau, in the brain. Recent evidence suggests that the glymphatic and meningeal lymphatic systems, which contribute to the removal of waste products from the brain, may play a role in AD. In particular, impaired drainage through the deep cervical lymphatic system may contribute to the accumulation of disease-related proteins.

The LymphDAD study is a prospective, single-center pilot study designed to explore whether surgically improving cervical lymphatic drainage may be associated with changes in biological markers, brain imaging, and cognitive and clinical measures in selected patients with AD who are not eligible for currently available disease-modifying treatments.

Five participants with AD will undergo a minimally invasive microsurgical procedure called lymphovenous anastomosis (LVA), in which small cervical lymphatic vessels are connected to nearby small veins to facilitate lymphatic drainage. During the procedure, a small sample of lymphatic fluid will also be collected for exploratory analysis of amyloid-beta and tau proteins.

Participants will undergo clinical and neuropsychological assessments, blood sampling, magnetic resonance imaging (MRI), and amyloid positron emission tomography (PET) before the procedure and during follow-up. Follow-up assessments will be performed at 1, 3, 6, and 12 months after surgery.

The study is exploratory and is not designed to demonstrate a definitive clinical benefit. Its primary purpose is to obtain preliminary information on the feasibility, safety, and possible biological and clinical effects of cervical LVA in AD, which may support the design of future controlled studies.

Read the detailed description

Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by the accumulation of amyloid-beta (Aβ) and pathological tau, accompanied by neuronal loss and progressive cognitive impairment. Recent evidence suggests that the glymphatic and meningeal lymphatic systems contribute to the clearance of brain waste products, including Aβ and tau, and that impaired drainage through the deep cervical lymphatic system may be involved in AD pathophysiology.

Emerging preclinical and clinical evidence has suggested that restoration or enhancement of cervical lymphatic drainage may represent a potential therapeutic approach. Preliminary clinical studies have reported possible improvements in cognitive and clinical measures and favorable changes in AD-related biomarkers following cervical lymphatic surgery, although the available evidence remains limited and further prospective studies are needed.

The LymphDAD study is a prospective, single-center, pilot interventional study designed to explore the effects of restoring cervical lymphatic drainage in selected patients with AD who are not eligible for currently available disease-modifying therapies. Five participants will be enrolled.

All enrolled participants will undergo cervical lymphovenous anastomosis (LVA). LVA is a minimally invasive supermicrosurgical procedure in which patent lymphatic vessels are connected to small-caliber cervical veins to facilitate lymphatic drainage. The procedure will be performed under general anesthesia with indocyanine green fluorescence lymphography to identify lymphatic vessels and assess anastomotic flow. A small sample of lymphatic fluid will be collected intraoperatively from a lymphatic channel already exposed during the procedure for exploratory analysis of Aβ and tau.

The study will evaluate changes in circulating biomarkers, including Aβ42, Aβ40, phosphorylated tau (p-tau181 and p-tau217), neurofilament light chain (NfL), and glial fibrillary acidic protein (GFAP). Exploratory analyses of Aβ and tau in intraoperative lymphatic fluid will also be performed.

Neuroimaging assessments will include structural magnetic resonance imaging (MRI) for brain volumetry and amyloid positron emission tomography (PET) for assessment of amyloid burden. Clinical and cognitive outcomes will be assessed using standardized instruments, including the Mini-Mental State Examination (MMSE), Montreal Cognitive Assessment (MoCA), Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog), Neuropsychiatric Inventory (NPI), Clinical Dementia Rating (CDR), and, when feasible, the EQ-5D quality-of-life questionnaire.

Assessments will be performed at baseline and during follow-up. Blood biomarkers will be assessed at baseline, 1 month, and 6 months. Cognitive and clinical assessments will be performed at baseline, 3, 6, and 12 months. MRI volumetry and amyloid PET will be repeated at 6 months.

The primary purpose of this pilot study is exploratory. Outcomes will be evaluated as changes from baseline within each participant. The study does not include a control group and is not designed to establish the efficacy of LVA or demonstrate a definitive clinical benefit. The results will provide preliminary information regarding the feasibility and safety of the procedure and its possible effects on biological, imaging, cognitive, and clinical parameters, supporting the design of future controlled clinical studies.

03

Conditions studied

  • Alzheimer
  • Alzheimer Dementia (AD)

Browse trials for

Keywords

  • Alzheimer Disease
  • Alzheimer Dementia
  • Lymphovenous Anastomosis
  • Cervical Lymphatic Drainage
  • Deep Cervical Lymphatic System
  • Glymphatic System
  • Meningeal Lymphatics
  • Lymphovenous Bypass
  • Amyloid Beta
  • Tau
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of Alzheimer's disease according to NIA-AA 2024 criteria.
  • Not eligible for other disease-modifying therapies.
  • Ability to personally provide written after clinical evaluation -of decisional capacity.

Exclusion criteria

Exclusion Criteria:

  • Coagulopathy or active infection of the head and neck region.
  • Prior extensive cervical lymph node dissection or radiotherapy.
  • Uncontrolled systemic disease or to general anesthesia.
  • Participation in another interventional trial within the previous 3 months.
  • Known or allergy to indocyanine green.
  • Evidence of alternative or concomitant causes of cognitive decline other than Alzheimer's disease, such as subdural hematoma, primary or brain , or normal-pressure hydrocephalus.
  • Current or recent treatment with or immunomodulatory therapy within the previous 3 months.
  • infectious disease within the previous 6 months.
  • Severe psychiatric disorder that could interfere with cognitive assessment or study participation.
  • Pregnancy or breastfeeding.
  • End-stage malignant disease with an estimated of less than 6 months.
  • History indicative of systemic disease.
  • Inability to personally provide valid .
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
5 participants (estimated)

Study arms

  • Experimental
    Cervical Lymphovenous Anastomosis (LVA)

    Participants in this single-arm pilot study will undergo cervical lymphovenous anastomosis (LVA), a minimally invasive supermicrosurgical procedure intended to enhance cervical lymphatic drainage. Patent cervical lymphatic vessels will be connected to small-caliber cervical venous branches under high magnification, with indocyanine green (ICG) fluorescence lymphography used to identify lymphatic vessels and assess anastomotic flow. A small sample of lymphatic fluid will be collected intraoperatively for exploratory analysis of amyloid-beta and tau biomarkers. Participants will continue standard-of-care treatment for Alzheimer's disease and other comorbidities throughout the study.

    Procedure: Cervical lymphovenous anastomosis (LVA)

Interventions

  • ProcedureCervical lymphovenous anastomosis (LVA)

    Microsurgical restoration of cervical lymphatic drainage by connecting patent lymphatic channels to small-caliber cervical venous branches. The procedure is performed along the posterior edge of the sternocleidomastoid muscle using supermicrosurgical techniques. Indocyanine green (ICG) fluorescence lymphography is used to identify lymphatic vessels and assess anastomotic flow. A small sample of lymphatic fluid is collected intraoperatively from a lymphatic channel already exposed during the procedure for exploratory analysis of amyloid-beta and tau biomarkers.

  • ProcedureCervical lymphovenous anastomosis (LVA)

    Microsurgical restoration of cervical lymphatic drainage by connecting patent lymphatic channels to small-caliber cervical venous branches. In this study, lymphovenous anastomoses will be created along the posterior edge of the sternocleidomastoid muscle using supermicrosurgical techniques. Indocyanine green (ICG) fluorescence lymphography will guide lymphatic identification and assess anastomotic patency. A small sample of lymphatic fluid will also be collected intraoperatively from an exposed lymphatic channel for exploratory biomarker analysis.

06

What researchers measure

Primary outcomes

  1. Change from baseline in plasma amyloid-beta concentrations

    Change from baseline in plasma amyloid-beta 42 (Aβ42) and amyloid-beta 40 (Aβ40) concentrations following cervical lymphovenous anastomosis (LVA).

    Time frame: Baseline, 1 month, and 6 months after LVA

  2. Change from baseline in plasma phosphorylated tau concentrations

    Change from baseline in plasma phosphorylated tau 181 (p-tau181) and phosphorylated tau 217 (p-tau217) concentrations following cervical LVA.

    Time frame: Baseline, 1 month, and 6 months after LVA

  3. Change from baseline in plasma NfL and GFAP concentrations

    Change from baseline in plasma neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP) concentrations following cervical LVA.

    Time frame: Baseline, 1 month, and 6 months after LVA

Secondary outcomes

  1. Change from baseline in Mini-Mental State Examination score

    Change in Mini-Mental State Examination (MMSE) score from baseline. The MMSE ranges from 0 to 30, with higher scores indicating better cognitive function.

    Time frame: Baseline to 3, 6, and 12 months after LVA

  2. Change from baseline in Montreal Cognitive Assessment score

    Change in Montreal Cognitive Assessment (MoCA) score from baseline. The MoCA ranges from 0 to 30, with higher scores indicating better cognitive function.

    Time frame: Baseline to 3, 6, and 12 months after LVA

  3. Change from baseline in Alzheimer's Disease Assessment Scale-Cognitive Subscale score

    Change in Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog) score from baseline. Scores range from 0 to 70, with higher scores indicating greater cognitive impairment.

    Time frame: Baseline to 3, 6, and 12 months after LVA

  4. Change from baseline in Neuropsychiatric Inventory score

    Change in Neuropsychiatric Inventory (NPI) total score from baseline. Scores range from 0 to 144, with higher scores indicating greater neuropsychiatric symptom burden.

    Time frame: Baseline to 3, 6, and 12 months after LVA

  5. Change from baseline in Clinical Dementia Rating score

    Change in Clinical Dementia Rating (CDR) global score from baseline. The CDR global score ranges from 0 to 3, with higher scores indicating greater dementia severity.

    Time frame: Baseline to 3, 6, and 12 months after LVA

Other outcomes

  1. Change from baseline in hippocampal volume on magnetic resonance imaging

    Change from baseline in automated hippocampal volume measured on structural magnetic resonance imaging (MRI).

    Time frame: Baseline and 6 months after LVA

  2. Change from baseline in cortical gray-matter volume on magnetic resonance imaging

    Change from baseline in automated cortical gray-matter volume measured on structural magnetic resonance imaging (MRI).

    Time frame: Baseline and 6 months after LVA

  3. Change from baseline in amyloid PET standardized uptake value ratio

    Change from baseline in global and regional cerebral amyloid burden quantified using standardized uptake value ratio (SUVr) on amyloid positron emission tomography (PET).

    Time frame: Baseline and 6 months after LVA

  4. Change from baseline in amyloid PET Centiloid value

    Change from baseline in cerebral amyloid burden quantified using the Centiloid scale on amyloid positron emission tomography (PET).

    Time frame: Baseline and 6 months after LVA

  5. Number of participants with procedure-related adverse events

    Number of participants experiencing one or more adverse events considered related to cervical lymphovenous anastomosis, including infection, hematoma, wound-healing complications, transient swelling, neurological deficits, or anastomotic thrombosis or failure.

    Time frame: From LVA through 12 months after surgery

  6. Number of participants with patent lymphovenous anastomosis

    Number of participants with intraoperative evidence of lymphovenous anastomotic patency demonstrated by indocyanine-green fluorescence lymphography.

    Time frame: During the LVA procedure

07

Study locations

1 of 1 sites recruiting
  • Azienda Ospedaliera Universitaria Le Scotte
    Siena, Tuscany 53100, Italy
    Recruiting
08

References and documents

Publications

  • Imholz C, Schaller C, Watson JA, Zurfluh CE, Grigorean A, Lindenblatt N. Robotic-assisted lymphovenous anastomosis to treat periorbital lymphedema and systematic review of lymphatic reconstruction of face and neck lymphedema. J Robot Surg. 2025 Jul 12;19(1):380. doi: 10.1007/s11701-025-02552-6. Xie Q, Pak CJ, Kwon J, Chao SC, Hong JP . Potential Role of Lymphovenous Bypass in Mitigating Alzheimer's Disease Dementia. Arch Plast Surg. 2025 Jul 23;52(4):247-252. doi: 10.1055/a-2627-9243. Chen JY, Zhao DW, Yin Y, Gui L, Chen X, Wang XM, Wang PB, Zuo CH, Lai ZP , Li C, Wang R, Xian JS, Chen Z, Feng H, Hu R. Deep cervical lymphovenous anastomosis (LVA) for Alzheimer's disease: microsurgical procedure in a prospective cohort study. Int J Surg. 2025 Jul 1;111(7):4211-4221. doi: 10.1097/JS9.0000000000002490. Ma X, Wang F, Wang G, Zhao M, Zheng Y, Guo Y, Wu J, Liu Y, Liu Y, He G, Ren L, Gong Z, Wang J, Chen L, Hu S, Chu Q, Li Z, Wu J, Li R, Zhang X, Shi Q, Lian H, Ye J. A surgical therapy for Alzheimer's disease with lymphaticovenular anastomosis. J Alzheimers Dis Rep. 2025 Oct 3;9:25424823251384244. doi: 10.1177/25424823251384244. Tang C, Zheng X, Li H, Wang B, Zheng Y, Song W, Wu A, Xin L, Zhang D, Yang R, Du S, He P , Li Y, Wu L, Wang X, Shi Q, Bernardes GJL. Deep cervical lymphatic-venous anastomosis in dementia: a clinical and mechanistic evaluation. Int J Surg. 2025 Dec 17. doi: 10.1097/JS9.0000000000004561. Wu C, Yuan J, Tian Y, Wang Y, He X, Zhao K, Huang J, Jiang R. Tauopathy after long-term cervical lymphadenectomy. Alzheimers Dement. 2025 Apr;21(4):e70136. doi: 10.1002/alz.70136. Jessup M, Iglesias NJ, Tadisina KK, Xu K, Mella-Catinchi J, Pinchuk L, Singh D, Tse DT, Nayak VV, Coelho PG. The emerging role of biomaterial applications in cerebral lymphatic surgical interventions: A narrative review. Biomater Biosyst. 2025 Aug 9;19:100117. doi: 10.1016/j.bbiosy.2025.100117. Hong JP , Chen WF, Nguyen DH, Xie Q. A Proposed Role for Lymphatic Supermicrosurgery in the Mana

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2026 (actual). Primary completion is estimated for Jul 2028, 24 months after the start.

Of 887 non-industry interventional studies with no phase under Alzheimer Disease, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 51. This study's planned 24 months is below that.

Counting every sponsor, half of 964 studies reached it within 29 months; a quarter within 15 and three quarters within 51.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 19, 2026
First posted
Oct 2, 2026
StartActual
Jul 1, 2026
Primary completionEst.
Jul 1, 2028
CompletionEst.
Dec 31, 2028
Last update
Oct 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 2, 2026
Show all 1 update
  1. Oct 2, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07854327
Lead sponsor
University of Siena
Responsible party
Paolo Gennaro (Professor, University of Siena) — Principal investigator
First posted
Oct 2, 2026
Start date
Jul 1, 2026
Primary completion
Jul 1, 2028 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Oct 2, 2026

Study contacts

Andrea Frosolini, MD
Contact
andreafrosolini@gmail.com
3939447318 ext. 0039
Carlo Manco, MD
Contact
carlooo95.CM@gmail.com
3460221117 ext. 0039
Paolo Gennaro, Professor
study chair · University of Siena, Department of Biotechnology
Domenico Plantone, Professor
principal investigator · University of Siena, Department of Neurology
Federica Orsini, MD
principal investigator · University of Siena, Department of Nuclear Medicine

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion